Skip to main content
OpenTrials
Completed

NCT Number: NCT02145377

PXVX0200 (CVD103-HgR) vs Shanchol in Mali

To compare the ability of a single dose of PXVX0200 at two different dose levels, to placebo to elicit a significant antibody response 14 days after vaccination, compared to baseline.

To compare the ability of a single dose of PXVX0200 to a comparator vaccine Shanchol, a two dose administration, to elicit antibody response by 14 days after vaccination.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Centre pour le Développement des Vaccins, Mali (CVD-Mali)

Bamako, Mali

About this study

Currently there are two licensed inactivated vibrio oral vaccines (Dukoral® [Crucell; Leiden, The Netherlands] and Shanchol™ [Shantha Biotechnics; Hyderabad, India]) that are pre-qualified by the World Health Organization (WHO) for procurement by United Nations (UN) agencies. Each of these vaccines requires a two-dose regimen which is difficult to implement in the face of explosive outbreaks of cholera in unsettled situations in developing countries. For this reason there is great interest in identifying a cholera vaccine that can provide rapid onset of protection following the ingestion of just a single oral dose.

This Phase 2 randomized, observer-blinded and subject-blinded clinical trial to be conducted in Bamako, Mali will assess the immunogenicity of the 10^8 cfu versus the 10^9 cfu formulation of PaxVax-manufactured CVD 103-HgR.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to understand the study and give consent (either written or through a process that involves audio tapes explaining all aspects of the study and the consent form in local languages [Bambara and French] followed by making a mark and signature by a literate witness)
  • Healthy men or women, age 18 to 45 years (inclusive) without significant medical history
  • Women of child-bearing potential must have negative urine pregnancy test at baseline, prior to vaccination. They must also be willing to use adequate birth control for the duration of the 28-day study and have additional pregnancy tests if indicated. Effective methods of birth control for this study include abstinence, intrauterine device (IUD), oral or depot contraceptive, or barrier plus spermicide
  • Willingness to remain in the study area until at least 42 days after receipt of the first vaccine dose

Exclusion criteria

  • Health care workers who have direct contact with patients who are immune deficient, HIV-positive, or have an unstable medical condition
  • Clinically significant history of immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurologic illness, psychiatric disorder requiring hospitalization, current drug or alcohol abuse
  • History of an abnormal stool pattern or regular use of laxatives
  • Previously received a licensed or investigational cholera vaccine
  • History of cholera illness

Treatment and study plan

PXVX0200 10E8

Biological

Oral dose of PXVX0200 10E8

PXVX0200 10E9

Biological

Oral dose of PXVX0200 10E9

Placebo

Biological

Oral dose of sodium bicarbonate buffer

Shanchol

Biological

Licensed comparator

Primary outcomes

  1. To elicit a significant rise in serum Inaba vibriocidal antibody after a single vaccination

    Time frame: 14 days

    A comparison of the ability of a single ≥2 x10E9 cfu oral dose versus a single ≥2 x10E8 cfu oral dose of PXVX0200 (CVD 103-HgR) versus placebo to elicit a significant (> 4-fold) rise in serum Inaba vibriocidal antibody 14 days after vaccination, compared to baseline

Secondary outcomes

  1. To measure antibody response for a 10E8 dose and 10E9 dose of PXVX0200 oral vaccine

    Time frame: 14 days

    To compare the ability of a single ≥2 x108 cfu dose of PXVX0200 (CVD 103-HgR) or ≥2 x109 oral dose of PXVX0200 (CVD 103-HgR) versus Shanchol™ to elicit serum Inaba vibriocidal antibody mean fold rise (compared to baseline titer) and GMT

  2. To plot the kinetics of the serum Inaba Vibriocidal antibody response

    Time frame: Baseline and post-vaccination time point.

    To plot the kinetics of the serum Inaba vibriocidal antibody response after ingestion of a single oral dose of PXVX0200 (CVD 103-HgR) containing ≥2 x10E8 cfu or ≥2 x10E9 cfu versus Shanchol™. (With GMT on the Y axis and time points on the X axis, the GMTs at baseline and at each post-vaccination time point will be connected as a line graph).

  3. Assess fecal shedding of PXVX0200

    Time frame: Day 1-3, day 7 and day 14

    Shedding of CVD 103-HgR in stool as determined by stool culture (whole specimen or rectal swab)

  4. Compare rate of diarrhea

    Time frame: 7 days

    To compare the rate of diarrhea (≥ 4 loose stools within 24 hours) following administration of each vaccine regimen versus placebo over 7 days of follow-up

Other outcomes

  1. Plot seroconversion

    Time frame: Day 7, 14, 21, 28, 35 and 42

    To plot the seroconversion (≥ 4-fold increase over baseline), mean fold rise (comparing baseline titer with post-vaccination titer), and kinetics of serum IgG cholera antitoxin antibody following the ingestion of a single oral dose of PXVX0200 (CVD 103-HgR) containing ≥2 x10E8 cfu or ≥2 x10E9 cfu versus Shanchol™.

  2. Assess reactogenicity

    Time frame: For seven days after each dose of PXVX0200

    Assess tiredness, vomiting, loss of appetite, abdominal pain and headache

Sponsors and collaborators

Lead sponsor

University of Maryland, Baltimore

Other

Collaborators

  • Emergent BioSolutions
  • Shantha Biotechnics Limited

Registry information

Official study title

A Phase 2 Randomized, Double-Blinded Study to Compare in Malian Adults the Immunogenicity, Clinical Acceptability and Excretion Pattern Following the Ingestion of a Single Dose of PXVX0200 (CVD 103-HgR) Live Oral Cholera Vaccine Containing Either 108 Colony Forming Units [Cfu] or 109 Cfu Using Shanchol™ Killed Whole Cell Oral Cholera Vaccine as an Immunological Comparator

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
May 22, 2014
Registry last updated
Sep 26, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.